Navigation Links
Microenvironment of hematopoietic stem cells can be a target for myeloproliferative disorders
Date:6/22/2014

The discovery of a new therapeutic target for certain kinds of myeloproliferative disease is, without doubt, good news. This is precisely the discovery made by the Stem Cell Physiopathology group at the CNIC (the Spanish National Cardiovascular Research Center), led by Dr. Simn MndezFerrer. The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).

The findings, published today in Nature, demonstrate that these myeloproliferative neoplasias only appear after damage to the microenvironment that sustains and controls the hematopoietic stem cellsthe cells that produce the cells of the blood and the immune system. Protecting this microenvironment, or niche, has thus emerged as a new route for the treatment of these diseases, for which there is currently no fully effective treatment.

"In normal conditions, the microenvironment is able to control the proliferation, differentiation and migration of the hematopoietic stem cell. A specific genetic mutation in these cells results in inflammatory injury to the microenvironment and this control breaks down. What our work shows is that this damage can be prevented or reversed by treatments that target the niche," explained Dr. Mndez-Ferrer.

Indeed, the same team of researchers has demonstrated the efficacy of a possible new treatment, which has been patented through the CNIC. The treatment involves an innovative use of clinically approved treatments for other diseases, so that, according to the authors, "it shouldn't be associated with adverse side effects". The new treatment route has been tested in animals and has received financial backing for a multicenter phase II clinical trial. "This study has a very strong translational and clinical potential", emphasized study first author Dr. Lorena Arranz, who added that "current treatment for myeloproliferative neoplasias is largely symptomatic and directed at preventing thrombosis and fatal cardiovascular events".

The only real cure available today is a bone marrow transplant, which is not advisable in patients over 50 years old. "This makes it important to identify new therapeutic targets for the development of effective treatments," the investigators conclude.


'/>"/>

Contact: AInhoa Iriberri
airiberri@cnic.es
34-610-295-556
Centro Nacional de Investigaciones Cardiovasculares
Source:Eurekalert  

Related medicine news :

1. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
2. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
3. New drug prevents spread of human prostate cancer cells
4. Tiny hitchhikers attack cancer cells
5. To prevent leukemias dreaded return, go for the stem cells
6. Scientists identify major source of cells defense against oxidative stress
7. Therapy exploits addiction of leukemia cells
8. IBN discovers human neural stem cells with tumor targeting ability
9. Leukaemia cells have a remembrance of things past
10. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
11. Research yields new clues to how brain cancer cells migrate and invade
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Microenvironment of hematopoietic stem cells can be a target for myeloproliferative disorders
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, ... Brake Technology (ABT), an innovative braking system that allows skaters of all levels ... one of the biggest concerns of beginner and intermediate skaters – learning how ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but ... patient. Dentists have several general anesthesia alternatives and finding the right option can result ... College in Tokyo, Japan wanted to find out which anesthetic was the better choice ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... of difference. Eden Activewear is a stand-out company for several differences from other ... and only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to ... Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. ... and pass through tough times, Dr. Bernie Siegel energizes listeners to live life ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017   Synthetic Biologics, Inc. (NYSE ... designed to preserve the microbiome to protect and ... to initiate a Phase 2b/3 adaptive pivotal trial ... lactone designed to reduce methane production by certain ... to treat the underlying cause of irritable bowel ...
(Date:1/18/2017)... PAUL, Minn. , Jan. 18, 2017 /PRNewswire-USNewswire/ ... developer of medical devices using neuroblocking technology to ... today announced the pricing of an underwritten public ... million, prior to deducting underwriting discounts and commissions ... The offering is comprised of Class A Units, ...
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
Breaking Medicine Technology: